Health and Well-Being

Maintaining stable blood glucose levels is central to achieving a healthier lifestyle and preventing metabolic disorders such as diabetes. Even for non-diabetic individuals, daily fluctuations in glucose can affect energy levels, focus, sleep quality, and long-term metabolic health. As awareness grows around personalized health tracking, consumers are increasingly seeking simple, non-invasive ways to understand how diet, exercise, and stress influence their glucose patterns. BGEM meets this need through a smartphone app that estimates blood glucose levels non-invasively using data from smartwatches, fitness trackers, and smart rings. By leveraging the photoplethysmography (PPG) sensors that users already wear, the app provides on-demand insights into glucose fluctuations without the need for finger pricks or patches. Powered by advanced algorithms in the cloud, the system translates wearable sensor data into personalized glucose trend information, allowing users to visualize how daily habits influence their metabolic responses. This empowers individuals to make informed lifestyle adjustments, supporting better nutrition choices, improved fitness outcomes, and early awareness of potential glucose irregularities. Unlike conventional continuous glucose monitors that rely on invasive sensors, this technology is completely non-invasive, affordable, and accessible, making proactive glucose monitoring possible for a broader health-conscious population. This solution is designed for consumers who want to take greater control of their wellness journey through meaningful, data-driven insights. The technology owner is seeking collaborations with hardware manufacturers for integration, wearable brands for product development, distributors and IHLs for expanding research. 

Wound healing is a complex process and is associated with multi-stage cell/tissue transformations. The entire wound healing process is generally complete around 20 days after skin injuries. Unfortunately, impaired wound healing, which usually occurs as a result of infection or the pathological status of the patients, i.e., diabetes, obesity, cancer, and in particular, severe inflammation, leads to excess exudate production and tissue ulcers, causing prolonged health problems and economic burdens for patients. This technology introduces a sterilized nanoemulgels xanthones (XTs-NE-Gs) which are compounds from mangosteen peel dispersed in a gel base. The methodology involves using a high pressure homogenization technique without the addition of organic solvents in the formulation to produce sterilized XTs-nanoemulsion (NE) concentrate. After blending sterilized XTs-NE concentrate and the sterilized gel, a sterilized XTs-NE-G was obtained.   The concentrate has proven effective enhancement activities on the proliferation and migration rates of skin cells. It also promoted re-epithelialization, collagen deposition and inflammation suppression in mice models. Xanthones has proven strong anti-oxidant, anti-inflammatory and anti-bacterial properties. The nanoemulgel technology can overcome the typical problems from the addition of some solubilizers to enhance solubility of XTs in the products, in particular, alcohol that cause burn sensation on the open wounds.  Importantly, the obtained product from this technology could be sterilized and thus safe for wound healing purpose. The technology owner is seeking collaborations for clinical trials to obtain information for supporting product safety and efficacy and manufacturers for scale up. 

While split-thickness autograft (STSG) combined with dermal substitutes remains the conventional procedure for burn wounds, evolving advancement in technologies have provided alternatives and multi-model treatment for deep burns which includes mechanisms such as dermal scaffolds, cellular therapies, anti-microbial dressings and regenerative adjuncts. This technology introduces a topical burn treatment formulated with Transition Metal Dichalcogenide (TMD), WS2 (tungsten disulfide) nanosheets as the key active ingredient. TMDs are a class of two-dimensional (2D) layered materials combining tunable electronic, optical, and catalytic properties with excellent mechanical flexibility and chemical stability. Traditional burn therapies mainly focus on anti-bacterial activity but often delay healing due to strong cytotoxicity. The TMD nanosheet formulation shows powerful anti-oxidant, anti-inflammatory, and anti-bacterial effects simultaneously. It efficiently scavenges reactive oxygen and nitrogen species (ROS/RNS), suppresses inflammatory cytokines, and reduces cell apoptosis—ultimately minimizing tissue damage and promoting faster wound recovery. These attributes make TMDs promising for next-generation biomedical materials, particularly in antibacterial coatings, wound dressings, and photothermal therapy—offering multi-functionality beyond traditional metallic or polymeric materials. Laboratory and animal studies have verified its efficacy and safety, suggesting strong potential for clinical translation once large-scale synthesis and formulation optimization are completed. The technology owner is seeking collaboration partners with:  Pharmaceutical and skincare companies Medical material manufacturers Clinical research institutions interested in nanomaterial-based drug delivery systems and topical wound-care products.

Speech and voice disorders can significantly affect a person’s ability to communicate and engage with others, especially during childhood development. While special education schools provide valuable support within their premises, there remains a critical need for tools that empower individuals to communicate more confidently in everyday environments. This assistive communication technology bridges that gap. It combines both hardware and software to help users, primarily children under 12, though suitable for anyone who requires speech assistance to express themselves more clearly. Importantly, the device is not meant to replace natural speech but to supplement it, providing users with an additional way to articulate words or phrases that may be difficult to pronounce. In doing so, it supports inclusive communication and helps individuals build confidence in social interactions. This technology can be deployed in collaboration with special education institutions, medical device manufacturers, and software developers focusing on speech therapy and assistive technologies.

This innovative technology addresses the critical challenge of complex medical information interpretation that patients face daily. The solution transforms healthcare delivery through artificial intelligence by providing hyper-personalized, patient-friendly care that makes medical data accessible and meaningful to patients. The platform empowers patients with AI agents that organize and decode complex medical information, delivering instant personalized answers through enterprise-grade medical chatbots and tailored tools with expert insights. The technology bridges the gap between complex medical terminology and patient comprehension, significantly reducing the time required to interpret and understand medical information. With over 600,000 patient-uploaded medical documents and 120,000 registered patients (70%+ cancer patients) and caregivers, the platform has demonstrated substantial market adoption. This solution provides comprehensive end-to-end healthcare support, seamlessly connecting the entire patient journey from screening to follow-up care through integrated data synchronization and HIPAA-compliant infrastructure. The technology owner is seeking collaborations with: Hospital systems (EMR, HER vendors) for integrated deployment. Telemedicine platforms requiring AI-powered patient support. Pharmaceutical companies developing digital therapeutics. Medical device manufacturers seeking patient education integration. Healthcare insurance providers implementing value-based care programs. Healthcare technology accelerators and innovation hub.

This technology presents a regenerative medicine approach for treating fingertip loss by using nail stem cells derived from human induced pluripotent stem (iPS) cells. The loss of fingertip can arise from burns, trauma accidents, crush injuries due to heavey machineries and tools. Fingertip amputations are currently managed with conservative treatments that often result in shortening and deformation, with limited options for restoring full form and function. By leveraging the regenerative potential of nail stem cells, this therapy aims to achieve structural and functional regeneration of the fingertip, including nail reconstruction. A patent has been filed for the method of generating nail tissues and nail stem cells from human iPS cells, supporting future clinical translation and application. Ideal Collaboration Partner: Pharmaceutical and biotechnology companies with an interest in advancing cell-based regenerative medicine therapies, particularly those with expertise in clinical development and commercialization.

Insurers are increasingly shifting from traditional static underwriting to data-driven models that leverage health data and medical records. With advances in digital health infrastructure and wider availability of electronic medical records, insurers can now assess risk more accurately and personalize premiums.  Beyond pricing, insurers are also using health data to incentivize preventive behaviors, rewarding policyholders who maintain healthier lifestyles with reduced premiums or benefits. This convergence of healthcare and insurance reflects a broader move towards proactive, personalized, and engagement-driven insurance models. This technology known as HealthGrade quantifies individuals health status based on digital health data such as health check-ups and medical usage history. By using it like a credit score in the credit market, HealthGrade aims to innovate insurance pricing and underwriting. It personalizes underwriting decisions beyond static rule-based methods. HealthGrade is currently used by insurers and helps develop health-promoting products offering financial rewards for healthier behaviors. This creates mutual value for insurers and consumers. The technology owner is seeking to partner with:  Insurance and Reinsurance companies Healthcare companies looking to leverage big data Government association for public health Regulatory sandbox entities in Asia 

The growing challenge of plastic waste and non-biodegradable absorbent materials is driving demand for bio-based alternatives that deliver performance without utilisation of petrochemicals. Poly-γ-L-glutamic acid (L-PGA) stands out as a biodegradable, biocompatible biopolymer with exceptional water retention and film-forming properties, making it highly relevant to applications requiring such functionalities. Commercial adoption has been limited as most commercial PGA is DL-PGA (a racemic polymer with lower stereoregularity and less predictable chemistry) while the preferred L-PGA grade remains scarce and costly under the single supplier archaea-based production route. This technology offers a cost-efficient and scalable platform for L-PGA production. Using proprietary microbial strains, it can produce consistent, ultra-high molecular weight L-PGA with stable quality and stereoregular purity. The resulting stereoregular L isomer material enables early adoption in cosmetics/personal care and medical materials, with the potential to expand into bio-based superabsorbent polymers (SAPs) and bioplastics as production capacity increases. To accelerate market adoption and tailor application-specific L-PGA grades, the technology owner seeks co-development and scale-up partners for this L-PGA technology (current readiness is at bench-scale, with next steps focused on jar-bioreactor scale-up and standardized testing).

The technology is an advanced Clinical Decision Support System (CDSS) designed to streamline and enhance the process of medication review, with a strong focus on safe deprescribing practices. Built on evidence-based guidelines and best clinical practices, the application provides healthcare professionals (doctors, pharmacists, and nurses) with reliable recommendations to optimize medication regimens, particularly for older adults who are at higher risk of polypharmacy and adverse drug events. This team-care deprescribing application can be seamlessly launched across various points of care: hospitals, clinics, nursing homes, or community health settings. This enables clinicians to work collaboratively in reducing medication burden while safeguarding patient safety. By integrating into existing workflows, it not only improves efficiency and decision-making but also supports higher standards of clinical care, leading to better health outcomes and quality of life for patients.